---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-22-000053"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:55:18.581485+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q3 revenue up 5% to $131.1M but net loss widens to $41.9M

## Summary
- Revenue $131.1M (+5% YoY, +14% QoQ); gross margin 77% (down from 80% in Q3 2021).
- Operating loss $40.0M vs $15.9M YoY; net loss $41.9M vs $17.2M YoY, including $33.5M stock-based compensation.
- FY2022 revenue guidance reaffirmed at $500-520M; cash & equivalents $452.4M at Sep 30, 2022.
- Highlights Xenium in situ platform launch expected later this year and long-read sequencing compatibility.

## SEC filing metadata
- accession: 0001770787-22-000053
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000053/0001770787-22-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000053/txg-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-22-000053
- JSON: https://secwatch.observer/filing/0001770787-22-000053.json
- Plain text: https://secwatch.observer/filing/0001770787-22-000053.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported the third quarter ended September 30, 2022 results: revenue $131.1 million, net income $41.9 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $131.1 million
  - Net income: $41.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue was $131.1 million for the third quarter of 2022, a 5% increase from $125.3 million for the corresponding prior year period. This increase was primarily driven by higher volume of units sold and growth due to new customers, partially offset by unfavorable foreign exchange fluctuations. Gross margin was 77% for the third quarter of 2022, as compared to 80% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix with newly introduced products and increased manufacturing and supply chain costs. Operating expenses were $140.7 million for the third quarter of 2022, a 21% increase from $116.7 million for the corresponding prior year period. This increase was driven by higher personnel expenses, including stock-based compensation and restructuring costs, increased costs for facilities and information technology to support operational expansion, and increased costs for laboratory materials and supplies to support research and dev
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000053/0001770787-22-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.